A new tool to evaluate kidney function developed by Swiss pharma firm Roche and which uses artificial intelligence has passed a regulatory test. The Chronic Kidney Disease algorithm panel has received the European CE marking of conformity, the Basel-based company announced on Monday. +Get the most important news from Switzerland in your inbox The new tool is designed to help assess the progression of kidney function loss. It can be used in patients diagnosed with chronic kidney disease and adults with diabetes or hypertension who are at high risk of reduced kidney function. “Chronic kidney disease affects more than 700 million people worldwide and is widely recognised as a global health challenge,” Roche said in a statement. “With early diagnosis and appropriate treatment, it is possible to delay or prevent the decline in kidney function and reduce cardiovascular health risks, as well as related healthcare costs.” The tool is already available in Europe and the United Kingdom, with …